Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer

Concurrent chemoradiotherapy (CCRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). The comparative merits of two widely used regimens: carboplatin/paclitaxel (PC) and cisplatin/etoposide (PE), each with concurrent radiotherapy, remain lar...

Full description

Saved in:
Bibliographic Details
Main Authors: Liew, Mun Sem, Sia, Joseph, Starmans, Maud H W, Tafreshi, Ali, Harris, Sam, Feigen, Malcolm, White, Shane, Zimet, Allan, Lambin, Philippe, Boutros, Paul C, Mitchell, Paul, John, Thomas
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2013
Subjects:
Clinical Cancer Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3892396/
https://ncbi.nlm.nih.gov/pubmed/24403265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.142
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items